# Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma

> **NCT02342782** · PHASE1 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 20 (actual)

## Conditions studied

- Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
- Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
- Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
- Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma
- Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** Yttrium Y 90 Basiliximab
- **DRUG:** Carmustine
- **DRUG:** Etoposide
- **DRUG:** Cytarabine
- **DRUG:** Melphalan
- **PROCEDURE:** Autologous Hematopoietic Stem Cell Transplantation
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT02342782
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-08
- **Primary completion:** 2020-09-18
- **Final completion:** 2024-11-18
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02342782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02342782, "Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02342782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*